GlobalRPH - Irritable-Bowel Syndrome News

Medical News

< back to feeds
Irritable-Bowel Syndrome News
Largest Gene Study In Childhood IBD Finds 5 New Genes In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease. A research team led by Hakon Hakonarson, M.D., Ph.D. ...more	16 Nov 2009
Lexicon Announces Positive Phase 2 Results Of LX1031 In Non-Constipating Irritable Bowel Syndrome Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). ...more	13 Nov 2009
Ironwood And Forest Announce Positive Linaclotide Results From Two Pivotal Phase 3 Trials In Patients With Chronic Constipation Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC). ...more	04 Nov 2009
New Tool To Accelerate Discovery Of Autoimmune Disease Mechanisms And Therapies Currently, 5 - 8% of the U.S. population is afflicted with an autoimmune disease. Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways. To help researchers investigate these common pathways, The Jackson Laboratory has published Pathways to Discovery: Autoimmune Diseases ( ...more	31 Oct 2009
Probiotic Is Effective Treatment For Colitis In Mice The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment. Colitis is a disease in which the inner tissue of the colon, the mucosa, becomes inflamed and damaged and can result in painful sores. ...more	27 Oct 2009
Possible Link Between Inflammatory Bowel Disease Treatment And Non-Melanoma Skin Cancer Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC). Dr. ...more	27 Oct 2009
The Bowels Of Infection Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology. CMV infects between 50% and 80% of adults in the United States. ...more	21 Oct 2009
Treatment For Inflammatory Bowel Disease Increases The Risk Of Infection-Related Cancers Patients with Crohn's disease or ulcerative colitis (collectively referred to as inflammatory bowel disease [IBD]) regularly receive treatment with thiopurine drugs to maintain remission. But an Article published Online First (http://www.thelancet. ...more	20 Oct 2009
Inflammatory Bowel Disease (IBD): Treatment Increases The Risk Of Infection-Related Cancers Ulcerative colitis or Crohn's disease is generally referred to as inflammatory bowel disease (IBD). Patients regularly receive treatment with thiopurine drugs to sustain remission. An article published Online First and in a future edition of The Lancet shows that this treatment increases the risk of malignant lymphoproliferative disorders (LD). Those are cancers associated with viral infection, particularly those linked to Epstein-Barr virus (EBV) infection. ...more	19 Oct 2009
Need For Surgery Almost Halved By Ulcerative Colitis Treatment A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. Ulcerative colitis, an inflammatory bowel disease (IBD) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. ...more	03 Oct 2009
Retinoic Acid May Alleviate Ulcerative Colitis And Similar Irritable Bowel Diseases Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases. Specifically they found that retinoic acid helps suppress out-of-control inflammation, which is a hallmark of active ulcerative colitis. ...more	02 Oct 2009
In Child Pain Relief, Antidepressant And Placebo Found To Be Equally Effective When used "off-label," the antidepressant amitriptyline works just as well as placebo in treating pain-predominant gastrointestinal disorders in children, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To view this article's video abstract, go to the AGA's YouTube Channel at http://www.youtube.com/AmerGastroAssn. ...more	02 Oct 2009
What Is Bowel Incontinence? What Is Fecal Incontinence? What Causes Bowel Incontinence? Bowel incontinence, also known as fecal (UK: faecal) incontinence, is an inability to control bowel movements. The person's stools (feces) leak from the rectum uncontrollably. Bowel incontinence can vary in severity from passing a small amount of feces when breaking wind, to total loss of bowel control. Bowel incontinence is a sign or symptom of a condition or disease; it is not a condition or disease in itself. ...more	30 Sept 2009
Mayo Clinic Researchers Lead National Clinical Trial Testing New Treatment For Chronic, Severe Indigestion Could medicines used for depression also treat chronic, severe indigestion? Scientists at Mayo Clinic suspect they can and, backed by funding from the National Institutes of Health (NIH), they are testing that premise in a nationwide clinical trial. "Nerve cells are found throughout the body, and just as their dysfunction in the brain can cause depression, we suspect overly sensitive nerves in the gut can produce this very uncomfortable indigestion," says Nicholas Talley, M.D., Ph. ...more	18 Sept 2009
Pharmos Announces Results Of Phase 2b Irritable Bowel Syndrome Study Pharmos Corporation (Pink Sheets: PARS) announced the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome. Although the primary efficacy variable (% of weeks responding for adequate overall relief of IBS symptoms) did not reach statistical significance, the percentage responding for the Dextofisopam 200 mg group was higher than that observed for the Phase 2a trial. ...more	15 Sept 2009
Soluble Fibre But Not Bran Effective At Treating Symptoms Of IBS Soluble fibre (psyllium) is an effective treatment for irritable bowel syndrome (IBS), but insoluble fibre (bran) may worsen symptoms, according to the first trial of increasing dietary fibre in a primary care setting, published on bmj.com. Irritable bowel syndrome is characterised by abdominal pain and an irregular bowel habit, and affects about 10% of the population. ...more	04 Sept 2009
Contrary To Insoluble Fiber, Soluble Fiber Is An Effective Treatment For Irritable Bowel Syndrome The first trial in increasing dietary fiber in a primary care setting is published on bmj.com today. It reports that soluble fiber (psyllium) is an effective treatment for irritable bowel syndrome (IBS). On the other hand, insoluble fiber such as bran may worsen symptoms. Irritable bowel syndrome is characterized by abdominal pain and an irregular bowel habit. It affects about 10 percent of the population. ...more	28 Aug 2009
Genetically Engineered Bacteria Are Sweet Success Against IBD For the first time, scientists have used a genetically engineered "friendly" bacterium to deliver a therapy. The treatment is for bowel disorders such as inflammatory bowel disease, which affects one in 400 people in the UK and for which there is no cure. The bacterium Bacteroides ovatus activates a protein when exposed to a specific type of sugar, xylan. ...more	22 Aug 2009
FDA: Cancer Warnings Required For TNF Blockers The U.S. Food and Drug Administration is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers. The warnings, which include an updated boxed warning, highlight the increased risk of cancer in children and adolescents who receive these drugs to treat juvenile rheumatoid arthritis, the inflammatory bowel disorder, Crohn's disease, and other inflammatory diseases. ...more	18 Aug 2009
Alternative Treatment For Irritable Bowel Syndrome When Conventional Therapy Has Failed IBS remains a common intestinal disorder causing significant discomfort and poor quality of life in patients who have the diagnosis. TCAs have been shown to improve abdominal pain in patients with IBS; however, there is insufficient evidence of global symptom relief. The search for an optimal treatment to improve symptoms and quality of life in IBS remains ongoing. A research article published in the World Journal of Gastroenterology addresses this problem. ...more	13 Aug 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 [Next] [Last Page]
Irritable-Bowel Syndrome News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.